Feature | December 13, 2010| Holly Worth

Wireless, Implantable Monitors Offer Long-Term Surveillance

Implantable cardiac monitors remain vigilant for rare syncope episodes and heart attacks

St. Jude Medicals Confirm ICM is used for patients with syncopes that are hard to detect. It can be used for up to three years to automatically record symptoms.

The Reveal XT comes with the externally carried, wireless Patient Assistant device. It allows patients to hit a record button to capture arrhythmias as they happen. A query button is programmed per physician-identified criteria to enable a status update.

The AngelMed Guardian System uses a pacemaker-size implantable monitor as an early warning system to detect coronary occlusion from thrombotic events, such as plaque ruptures.

In a world where everything is unplugged and cordless is king, cardiology is constantly searching for and developing the technology to make patient care both better and more convenient.

Implantable cardiac monitors (ICMs) are the latest technology on the medical market to satisfy both those qualifications. Invasive and longer lasting than their predecessors, the Holter and loop event monitors, give patients freedom and doctors remote access to syncopal information. This combination results in better diagnosis of cardiac conditions like syncope, atrial fibrillation and other irregularities.

“Before we had this technology, we relied on event monitors that could only function for a max of 30 days,” said Jaymie Hitchcock, director of heart rhythm management department, Mid-America Cardiology, Kansas City, Kan. and Mo. The practice group uses St. Jude Medical’s Confirm ICM, FDA-approved in late 2008. “For patients with syncopes every six months, that’s hard. With this, though, it’s a simple procedure — easy to implant — it can be used up to three years, and it’s automatically recording the symptoms.”

Hitchcock, whose clinic sees a range of patients, said ICMs are not for everyone. Holter monitors, which examine every heartbeat for 24-48 hours, and event loop monitors, which function for 30 days, are tried-and-true recorders for patients with frequent or dependable symptoms.

For patients with rare syncope or presyncopal episodes, however, ICMs are revolutionizing diagnosis and understanding. Blair Grubb, M.D., director of cardiac electrophysiology service, University of Toledo School of Medicine, Toledo, Ohio, sees nothing but those patients in his syncope clinic. For his practice, the development of ICMs has been invaluable. Grubb uses the Medtronic Reveal XT, commercially available since February 2009.

“Previously when doing evaluations, it used to be a leap of faith,” he said. “Now, we can see real-world events as they occur. Now, we see that things are much different than we thought they were. We didn’t fully understand or have a grasp on how [syncopes and other cardiac irregularities] were occurring.”

Syncope can be infrequent, intermittent and seemingly unexplainable. Possible causes include exercise, arrhythmias and other cardiac conditions, and while syncope’s origins are wide-ranging, at least 10 percent of syncope patients’ causes remain unidentified (1). But by evaluating heart rhythm signals over long periods of time, ICMs like the Reveal XT and the Confirm are able to better illuminate the problems to allow doctors to give a more accurate diagnosis.

An Advance Over Holter Technology
Insertable cardiac monitors are meant for different patients, as opposed to their long-established heart-monitoring alternatives. They not only have a longer lifespan, they also utilize different technology. Holter monitors are portable devices connected to the body with electrodes that record electrical signals from the heart. The signals transfer to logging equipment, which attaches to a belt loop or a necklace. ICMs, on the other hand, are approximately the size of a thumb drive, are implanted subcutaneously and require no external wires or patches. Grubb said his experience with ICMs is not only that they work, but also that they’ve gotten better.

“The initial [models] were fairly primitive, but so were cell phones,” he says. “Initially, these had to be patient-activated, but now they record automatically.”

Patient ECGs Available 24/7
Medtronic CareLink Network reads the Reveal XT’s data from a monitor connected to a phone line, which then dials a preprogrammed number to send the information to a Medtronic website. After that, the information is available remotely via the Internet by the physician — at any time and without an appointment. Not only does this make information more accessible, but Grubb said it also gives peace of mind to those fitted with the ICM. “Patients feel reassured to be able to be monitored anywhere in the country,” he said. “It’s like being monitored 24/7 for three years.”

Hitchcock has also seen the benefits of ICMs’ remote capabilities. Confirm monitors connect to the St. Jude Merlin @home Transmitter, which similarly receives information, connects to a phone line and then transfers the data to a website. Remote followups are scheduled daily, often when a patient sleeps. Mid-America Cardiology, which has locations across eastern Kansas and western Missouri, can now consult patients that live five to six hours away. “Having the convenience to ask the patient to send the information from their bedroom and troubleshoot and figure out what’s been going on has made a huge difference,” she said.

Ruling out a heart rhythm irregularity or tracking it is, according to Hitchcock, one of the technology’s greatest strengths. Specialists who deal with syncopal patients, such as Grubb and Hitchcock, are now able, with the help of technology, to better determine the root of the problem.

“The goal of Norman Holter [the inventor of Holter monitors] was to be able to record and differentiate phantom arrhythmias. That was in 1964, and there were always people who were told they were crazy,” Grubb said. “Today, it’s amazing to see events as they actually happen — not as you project them to be and not as you think they are, but as they really are.”

Cost vs. Benefits
Patients suffering from heart irregularities are not likely to see only physical benefits of this technology. Although he cited occasional reimbursement issues, Grubb points to the 2002 randomized assessment syncope trial (RAST) study to show that a prolonged monitoring strategy is more cost-effective than conventional testing in patients with unexplained syncope. And because patients using a monitor like the Confirm or Reveal XT often suffer from rare syncopal events, Hitchcock points out that the one-time cost of inserting a more costly monitor generally outweighs the more-frequent cost of a Holter or loop event monitor.

References:
1. Kanjwal, Khalil et al. “Psychogenic Syncope? A Cautionary Note.” Pacing and Clinical Electrophysiology, July 2009, vol. 32, issue 7, pages 862–865.

Related Content

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies| December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio.  Image courtesy of Joe Carfora.

Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio. 
Image courtesy of Joe Carfora.

News | November 25, 2017
November 25, 2017 — Sitting in, or standing close to the charging port of a Tesla electric vehicle did not trigger a
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization
News | Pacemakers| November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation| November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was the No. 1 most popular article on DAIC in October.

Feature | November 03, 2017 | Dave Fornell
November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Card
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab| October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Videos | EP Mapping and Imaging Systems| October 24, 2017
This video, provided by Acutus Medical, demonstrates a patient case showing the use of the AcQMap high-resolution ele
Overlay Init